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ABSTRACT
Objective: The objective of this study is to identify and analyze drug dosing in renally impaired patient in a tertiary care teaching hospital and to 
categorize patients on the basis of gender, age, glomerular filtration rate (GFR), and anemia.
Methods: A prospective, interventional study was conducted on the drug dosage in renally impaired patient by identifying, analyzing, and adjusting. 
Ethical clearance was obtained from the Institutional Ethical Committee. The study was conducted on 103 patients with renal impairment for 
6 months. During ward rounds, cases were collected, and collected data were assessed and analyzed using Micromedex, Lexicomp. For the possible 
interventions, the dosage errors were reported along with the evidence.
Results: Out of the 103 patients, 73 were males, and 30 were females, and majority of patients belonged to the age group between 41 and 65 years. 
About 56.31% and 43.69% of patients were in the Category B and Category C of GFR, respectively. A total of 244 comorbidities were present in 
103 patients with hypertension and Type 2 diabetes mellitus the foremost. In total, 983 drugs were prescribed to the total patient with an average of 
9.54 drugs per patient, 175 drugs required dosage adjustment.
Conclusion: The present study effectively reports all the interventions to the physicians along with the supporting data. Continuous medical education 
to the physicians together with pharmacists may reduce the chances of incongruity in drugs given to the renally impaired patients.
Keywords: Renal impairment, Modification of diet in renal disease, Creatinine clearance, Dosage adjustment.
INTRODUCTION
Renal failure is a condition where the kidneys lose their normal 
functionality. It is characterized by the reduction in the excretory and 
regulatory functions of the kidney. It usually occurs at the terminal 
stages of the disease process. Kidney failure - when one or both kidneys 
are not able to perform their usual functions. The main function of the 
kidney is to remove waste from the body and to balance the water and 
electrolyte content of the blood by filtering the salt and water in the 
blood. The waste and water excreted by the kidneys combine to form 
urine [1].
Treatment of renal failure may include medical management, dialysis, 
lifestyle changes, organ transplants, and immune suppressive therapy. 
Lack of adherence to prescribed renal failure treatments is a public 
health issue, as it is a major contributor to poor outcome [2].
Types of renal failure
Acute renal failure
The kidneys abruptly stop working entirely or almost entirely but may 
eventually recover to nearly normal function.
Chronic renal failure
An irreversible and progressive loss of renal functions, resulting in 
a variety of clinical and laboratory changes due to reduced renal 
excretory, endocrine, and regulatory functions [1].
Unpleasant effects of renal impairment
Impairment or degeneration of kidney function affects the 
pharmacokinetics of drugs. Some of the more common causes of 
kidney failure include disease, injury, and drug intoxication. Acute 
diseases or trauma to the kidney can cause uremia, in which glomerular 
filtration is impaired or reduced, leading to accumulation of excessive 
fluid, and nitrogenous products in the body. Uremia generally reduces 
glomerular filtration and/or active secretion, which leads to a decrease 
in renal drug excretion resulting in a longer elimination half-life of the 
administered drug [3].
Decreased drug clearance results in higher drug concentrations 
and hence greater drug effects. To avoid harm when drug clearance 
is significantly decreased, the dose of renally cleared drugs should 
generally be reduced in patients with renal disease [4].
Assessment of kidney function
•	 Serum	creatinine
•	 Creatinine	clearance	[5].
Dosage adjustment in renal impairment
Dosage regimen adjustment is mainly considered in renal diseases, when 
the drug is mainly (at least 70% of the dose) excreted by the kidney either 
unchanged or as an active metabolite or the therapeutic window of the 
drug or the metabolite is narrow. Dosage regimen adjustment options 
involve (i) reduction of the dose level, (ii) extension of the dosing interval, 
(iii) administration of a loading dose, and/or (iv) therapeutic drug 
monitoring. The proper dosing of medications for patients with renal 
impairment can maximize therapeutic efficacy and minimize toxicity. 
Proper dosing can also have an economic impact on the health system [6].
Objectives
To identify and analyze drug dosing in renally impaired patient in a 
tertiary care teaching hospital and to categorize patients on the basis of 
gender, age, glomerular filtration rate (GFR), and anemia.
© 2017 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
org/licenses/by/4. 0/) DOI: http://dx.doi.org/10.22159/ajpcr.2017.v10i4.16886
Research Article
378
Asian J Pharm Clin Res, Vol 10, Issue 4, 2017, 377-379
 Mrudangsinh et al. 
METHODS
A prospective, interventional study was conducted for 6 months in the 
Nephrology Department, Emergency Unit, Intensive Care Unit, general 
wards and dialysis unit of a tertiary care teaching hospital. All renally 
impaired patients above the age of 18 years of either sex with serum 
creatinine above 1.4 mg/dl or GFR below 50 ml/min/1.73 m2 were 
included in the study, whereas patients with chronic kidney disease 
(CKD) Stage 1 and 2 along with pregnant women and comatose patients 
were excluded from the study.
Ethical issues
The ethical clearance for the study was obtained from Institutional 
Ethical Committee of Bapuji Pharmacy College, Davangere.
Study procedure
The ward rounds were attended every day along with a nephrologist 
and patient details from patient profile form was collected to 
specially designed data collection form. The collected data was 
assessed and analyzed to identify dosing errors in medication chart 
using Martindale Complete Drug Reference, Micromedex, Lexicomp, 
British National Formulary and Research articles and Journals. 
For possible interventions, the dosage errors were reported to the 
nephrologist and other consulting physicians along with supporting 
data. The collected data were analyzed by applying suitable 
statistical method.
RESULTS
A total of 103 patients prescriptions were collected, out of which 
73 (70.87%) were males and 30 (29.13%) were females. Out of 
103 patients analyzed, majority of patients were in the age group of 
41-65 years (n=62, 60.19%), followed by >65 years (n=21, 20.39%), 
and 18-40 years (n=20, 19.42%). Among the total 103 patients, 
58 patients (56.31%) belong to the Category B, followed by 
45 patients (43.69%) in the Category C while analyzing the GFR. Out of 
103 patients, 54 patients (52.43%) have moderate anemia followed by 
37 patients (35.92%) with mild anemia and 12 patients (11.65%) with 
severe anemia. Totally, 40 patients (38.83%) among the 103 patients 
were found with two comorbidities, followed by 27 patients (26.21%) 
with three comorbidities, 22 patients (21.36%) with one comorbidity, 
10 patients (9.70%) with four comorbidities, 3 patients (2.93%) with 
five comorbidities, and only 1 patient (0.97%) with six comorbidities. 
Average number of comorbidities per patient was 2.37. A total of 244 
comorbidities were present in 103 patients, with hypertension (HTN) 
(27.87%) and Type 2 diabetes mellitus (DM) (19.67%) the foremost, 
followed by cardiovascular disorders, respiratory tract infections, 
urinary disorders, and central nervous system disorders.
In total, 983 drugs were prescribed to the entire 103 study population 
with an average of 9.54 drugs per patient. Minimum number of drugs 
prescribed to the patient was 5 and maximum were 17. Among the 
103 study population, 16 patients received 10 drugs per prescription. 
Out of 983 (100%) drugs prescribed to patients, 175 (17.80%) drugs 
required dosage adjustment (Table 1).
Out of 175 drugs requiring dosage adjustment, only 92 drugs were 
prescribed in adjusted dose. From the total 103 renally impaired 
patients, 51 patients (49.51%) required interventions. Antimicrobials 
(32%) are the most frequently prescribed class of drug which require 
dosage adjustment followed by antihypertensives (22.86%), antiplatelet 
(6.29%), opioids (5.14%), antiepileptics (4.57%), antiemetics (4%), 
H2 receptor antagonist (2.29%), genitourinary agents (2.29%), oral 
hypoglycemic agents (1.71%), calcium supplements (1.14%), nootropic 
agents (1.14%), antihistaminics (0.57%), antipsychotics (0.57%), 
xanthine oxidase inhibitor (0.57%), and cardiovascular agents (0.57%) 
(Table 2).
From the 56 antimicrobials requiring adjustments, 31 were not 
adjusted properly. Among commonly prescribed antimicrobials, the 
main class which was not modified as per the creatinine clearance was 
fluoroquinolones followed by nitro compounds (Table 3).
Among the 40 antihypertensive drugs requiring adjustments, 13 drugs 
were not adjusted, with diuretics being the foremost (Table 4).
DISCUSSION
The study was conducted for a period of 6 months and data of 
103 patients, who satisfied the inclusion criteria, were analyzed in a 
prospective manner. The degree of renal impairment was assessed 
Table 1: Determination of requirement of dosage adjustment in 
renally impaired patients
Total number of 
drugs
Number of drugs 
requiring dosage 
adjustment




Table 2: Distribution of drugs requiring dosage adjustments in 
renally impaired patients
S.No. Class of drugs Number of drugs n=175 (%)
1 Antimicrobials 56 (32)
2 Antihypertensives 40 (22.86)
3 Analgesics and antipyretics 25 (14.29)
4 Antiplatelet 11 (6.29)
5 Opioids 9 (5.14)
6 Antiepileptics 8 (4.57)
7 Antiemetics 7 (4)
8 H2 receptor antagonist 4 (2.29)
9 Genitourinary agents 4 (2.29)
10 OHA 3 (1.71)
11 Calcium supplements 2 (1.14)
12 Nootropic agents 2 (1.14)
13 Antihistaminics 1 (0.57)
14 Antipsychotics 1 (0.57)
15 Xanthine oxidase inhibitor 1 (0.57)
16 Cardiovascular agents 1 (0.57)
OHA: Oral hypoglycemic agents
Table 3: Distribution of antimicrobials





1 Penicillins 18 4
2 Fluoroquinolones 14 14
3 Cephalosporins 9 3
4 Nitro compounds 8 7
5 Carbapenems 2 -
6 Sulfonamides 1 1
7 Aminoglycosides 1 1
8 Imidazole agonists 1 -
9 Polymyxin antibiotic 1 1
10 Macrolide antibiotic 1 -
Table 4: Distribution of antihypertensives





1 Centrally acting drugs 17 1
2 Diuretics 13 5
3 Alpha-antagonists 4 4
4 ACE inhibitors 3 2
5 Vasodilators 2 -
6 Beta blockers 1 1
ACE: Angiotensin-converting-enzyme
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by calculating creatinine clearance using modification of diet in renal 
disease equation as that of a study conducted by Sepideh et al. and 
Markota et al. [7,8].
The study explores the dominancy of males over females in the 
development of renal impairment as similar to that of a study performed 
by Alahdal and Elberry and Henok et al. with a male population of 55% 
on both [9,10]. Among the total 103 patients, 73 patients (70.87%) 
were males and 30 patients (29.13%) were females in our study.
The study enrolled all renally impaired patients above the age of 
18 years, and majority of patients belong to the age group of 41-65 years 
(60.19%) as that of a previous study carried out by Kidu et al. where the 
predominance of the age group 41-65 was found to be 32% [11].
As in the present study, moderate renal impaired patients (56.31%) were 
also mostly reported in a study conducted by Sah et al. (62.41%) [12]. 
Based on the creatinine clearance, patients were grouped into three 
categories as Category A (GFR >50 ml/min/1.73 m2), Category B (GFR: 
10-50 ml/min/1.73 m2), and Category C (GFR <10 ml/min/1.73 m2).
The study classified the patients based on their hemoglobin (Hb) 
level as mild (Hb: 10-12 g/dl), moderate (Hb: 6-10 g/dl) and severe 
(Hb <6 g/dl) since reduction in Hb level is a common phenomenon 
associated with kidney dysfunction. Most of the patients belong to the 
moderate category of anemia with 52.43%.
The most frequent comorbidities linked with renal impairment are HTN 
and Type 2 DM since these two conditions can lead to the progressive 
damage of kidneys, which supports our study outcome where HTN was 
found to be 27.87%, and Type 2 DM was found to be 19.67% of total 
comorbidities.
Of the 103 patients evaluated, 51 patients required interventions 
with the percentage of 49.51%. Remaining patients were received 
with either already adjusted drugs or drugs that do not need any dose 
modification.
All patients included in the study were receiving a minimum of 5 drugs 
and a maximum of 17 drugs with an average of 9.54 drugs per patient. 
The total number of drugs received by the subjects was 983.
Out of the 983 drugs prescribed, 175 drugs (17.8%) required dosage 
adjustment, among which 92 drugs were already adjusted. One of the 
previous studies conducted by Erler et al. identifies 25% requirement 
of dosage adjustment in drugs given to the CKD patients [13].
In the current study, the most inappropriately prescribed class of drugs 
was antimicrobials (32%), and it coincides with the results of the 
studies conducted by Prajapati and Ganguly [14] (80%) and Kidu et al. 
(59.2%) [11]. Among the antimicrobials, dosage adjustments were 
required mostly for penicillins and fluoroquinolones. Antihypertensives 
were the class of prescribed drugs requiring dosage adjustment with 
centrally acting drug, clonidine being the foremost.
The study was concerned with the analysis of drugs prescribed to the 
renally impaired patients and to identify the appropriateness of dosage 
modification of renally excreted drugs by mainly using Micromedex and 
Lexicomp as leading sources.
CONCLUSION
To conclude, the current study provides insights into the need of dosage 
adjustments in renally impaired patients and appropriateness of drugs 
provided to them. Dosages of drugs given to the subjects were analyzed 
using Micromedex and Lexicomp as leading sources.
This study emphasizes the importance of improving the identification 
of patients with renal dysfunction, estimating their CrCl and 
implementing appropriate dose adjustments according to these 
estimates. This study improves patient-specific outcomes such as 
updated information to assist dosage guidelines, access to individuals 
trained in pharmacokinetics, implementation of pharmacokinetic 
dose consultation services in departments of clinical pharmacy, a 
continuous review of medication chart by the clinical pharmacist can 
reduce the frequency of inappropriateness in the drugs provided to 
the really impaired patients. The present study effectively reports all 
the interventions to the physicians along with the supporting data. 
Continuous medical education to the physicians together with clinical 
pharmacists can reduce the chances of inappropriateness in drugs 
given to the renally impaired patients.
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